PhaseBio Pharmaceuticals, Inc.
PhaseBio Pharmaceuticals, Inc. (PHASQ) Stock Overview
Explore PhaseBio Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
0
P/E Ratio
-15.72
EPS (TTM)
$-2.14
ROE
0.00%
PHASQ Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of PhaseBio Pharmaceuticals, Inc. (PHASQ) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.00.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -15.72 and a market capitalization of 0. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.